Sign In
Buy ALNY
$291.22
-6.47 (-2.17%)
At Close: Jun 10, 2026
Alnylam (ALNY) Up 7.4% Since Last Earnings Report: Can It Continue?
12:57pm, Thursday, 02'nd Sep 2021
Alnylam (ALNY) reported earnings 30 days ago. What's next for the stock?
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
04:00pm, Wednesday, 01'st Sep 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following
Will Alnylam Stock Continue To Make New Highs?
09:00am, Monday, 30'th Aug 2021
Going by historical performance, there is a slightly higher chance of more gains in ALNY stock over the next month.
Alnylam Pharmaceuticals Flying High Despite Limited Near-Term Clinical Catalysts
07:31pm, Tuesday, 10'th Aug 2021
Alnylam reported second quarter results that included modest outperformance in product revenue, including 12% qoq growth in Onpattro. 2022 should be a big year for the ATTR-CM program, with APOLLO-B r
Alnylam's (ALNY) Q2 Earnings Miss Estimates, 2021 Guidance Up
01:44pm, Wednesday, 04'th Aug 2021
Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021.
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q2 2021 Results - Earnings Call Transcript
03:31pm, Tuesday, 03'rd Aug 2021
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q2 2021 Results - Earnings Call Transcript
Alnylam Pharmaceuticals (ALNY) Reports Q2 Loss, Tops Revenue Estimates
10:42am, Tuesday, 03'rd Aug 2021
Alnylam (ALNY) delivered earnings and revenue surprises of -2.55% and 10.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
PeptiDream Inks $2.2B Deal To Broaden Alnylam's siRNA Delivery Scope
09:29am, Friday, 30'th Jul 2021
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and PeptiDream Inc have announced a license and collaboration agreement to discover and develop peptide-siRNA conjugates to deliver RNAi therapeutics to
Alnylam's Lumasiran Substantially Reduces Plasma Oxalate Levels PH1 Patients With Severe Renal Impairment
10:21am, Thursday, 29'th Jul 2021
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in primary hyperoxaluria type 1 (PH1) associated with progressive de
Analysts Estimate Alnylam Pharmaceuticals (ALNY) to Report a Decline in Earnings: What to Look Out for
04:07pm, Tuesday, 27'th Jul 2021
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What Drove Gene Editing Stocks Higher This Week
12:48pm, Friday, 02'nd Jul 2021
The most exciting clinical trial data in the medical community has huge implications for Intellia, and its peers.
What's Next For Alnylam Stock After The Recent Positive Development For Intellia?
08:30am, Thursday, 01'st Jul 2021
The stock price of Alnylam Pharmaceuticals, a pharmaceutical company focused on RNA interference therapeutics for genetically defined diseases, has seen a 4.1% drop over the last five trading days, af
Alnylam's (ALNY) NDA For Vutrisiran Gets FDA Acceptance
11:16am, Friday, 25'th Jun 2021
The FDA accepts Alnylam's (ALNY) NDA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. A decision is due on Apr 14, 2022.
What's Next For Alnylam Stock After The Recent 22% Rise?
09:30am, Friday, 11'th Jun 2021
The stock price of Alnylam Pharmaceuticals, a relatively smaller pharmaceutical company with a market capitalization of $18 billion, has seen a 22% rise over the last twenty-one trading days, and we b
Alnylam Announces Positive Early Results on Clinical Outcome Measures from ILLUMINATE-A Phase 3 Study of OXLUMO® (lumasiran)
07:00am, Monday, 03'rd May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive early results on clinical outcome measures from the 12-
